A previous article in this series focused on the questions of why and when a company would submit a monograph to the pharmacopoeias (1). This article details the more operational aspects of monograph ...
The European Pharmacopoeia Commission re-evaluates its policy on the development of monographs for finished drug products. The European Pharmacopoeia (Ph.Eur.), which is celebrating its 50th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback